Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome
AIM: To compare safety and efficacy of intravitreal dexamethasone (IVD) implant with topical nepafenac (TN) 0.1% in previously untreated Irvine-Gass syndrome (IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber int...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2019-02-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.cn/en_publish/2019/2/20190212.pdf |
| _version_ | 1811205400529207296 |
|---|---|
| author | Hande Guclu Vuslat Pelitli Gurlu |
| author_facet | Hande Guclu Vuslat Pelitli Gurlu |
| author_sort | Hande Guclu |
| collection | DOAJ |
| description | AIM: To compare safety and efficacy of intravitreal dexamethasone (IVD) implant with topical nepafenac (TN) 0.1% in previously untreated Irvine-Gass syndrome (IGS) in clinical practice.
METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens (IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study chart (ETDRS), slit-lamp, intraocular pressure (IOP) measurement, fundus examination, spectral-domain optical coherence tomography (OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6mo.
RESULTS: The mean BCVA of the IVD group was 49.3±6.8, and the mean BCVA of the TN group was 32.9±7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness (CRT) of IVD group was 266.6±53.5 µm and the mean CRT of TN group was 364.9±56.3 µm in post-treatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group.
CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6. |
| first_indexed | 2024-04-12T03:30:56Z |
| format | Article |
| id | doaj.art-2f6cacc7eaa141a09bbd0a5b28278d62 |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-04-12T03:30:56Z |
| publishDate | 2019-02-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-2f6cacc7eaa141a09bbd0a5b28278d622022-12-22T03:49:33ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982019-02-0112225826710.18240/ijo.2019.02.12Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndromeHande Guclu0Vuslat Pelitli Gurlu1Department of Opthalmology, Trakya University, Faculty of Medicine, Edirne 22030, TurkeyDepartment of Opthalmology, Trakya University, Faculty of Medicine, Edirne 22030, TurkeyAIM: To compare safety and efficacy of intravitreal dexamethasone (IVD) implant with topical nepafenac (TN) 0.1% in previously untreated Irvine-Gass syndrome (IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens (IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study chart (ETDRS), slit-lamp, intraocular pressure (IOP) measurement, fundus examination, spectral-domain optical coherence tomography (OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6mo. RESULTS: The mean BCVA of the IVD group was 49.3±6.8, and the mean BCVA of the TN group was 32.9±7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness (CRT) of IVD group was 266.6±53.5 µm and the mean CRT of TN group was 364.9±56.3 µm in post-treatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group. CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6.http://www.ijo.cn/en_publish/2019/2/20190212.pdfintravitreal dexamethasone implantnepafenacirvine-gass syndromecystoid macular edemainflammation |
| spellingShingle | Hande Guclu Vuslat Pelitli Gurlu Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome International Journal of Ophthalmology intravitreal dexamethasone implant nepafenac irvine-gass syndrome cystoid macular edema inflammation |
| title | Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome |
| title_full | Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome |
| title_fullStr | Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome |
| title_full_unstemmed | Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome |
| title_short | Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome |
| title_sort | comparison of topical nepafenac 0 1 with intravitreal dexamethasone implant for the treatment of irvine gass syndrome |
| topic | intravitreal dexamethasone implant nepafenac irvine-gass syndrome cystoid macular edema inflammation |
| url | http://www.ijo.cn/en_publish/2019/2/20190212.pdf |
| work_keys_str_mv | AT handeguclu comparisonoftopicalnepafenac01withintravitrealdexamethasoneimplantforthetreatmentofirvinegasssyndrome AT vuslatpelitligurlu comparisonoftopicalnepafenac01withintravitrealdexamethasoneimplantforthetreatmentofirvinegasssyndrome |